HFA 23: The DELIVER Phase III Trial

Подробнее о видео

In this short interview, Prof Martin Cowie (Clinical Vice-President AstraZeneca R&D & Honorary Consultant Cardiologist, Guy’s & St Thomas’ NHS Foundation Trust, London, UK) joins us to discuss the findings from a prespecified analysis of the DELIVER trial which covered the characteristics, outcomes and effects of dapagliflozin according to the duration of heart failure.

DELIVER was a randomized, double-blind, placebo-controlled trial which tested the hypothesis that dapagliflozin would reduce cardiovascular death or worsening HF in patients with HFmrEF or HFpEF.

Prof Cowie reveals the insights from this prespecified analysis, which suggest that the relative benefit of dapagliflozin was the same irrespective of the duration of heart failure, and the benefit of the drug was greater if the patients' event rate was higher.

Interview Questions:
-What was the reasoning behind this trial?
-Please tell us more about the mechanism of action behind dapagliflozin?
-What was the patient population and study design?
-What were the key results revealed at HFA 23?
-How should these findings impact practice and future research?
-What surprised you about the results of DELIVER?

Recorded remotely from London, 2023.

Visit Radcliffe Cardiology:

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook:
Follow us on Twitter: